[en] A look inside the JRTR reactor hall. Following its construction on the campus of the Jordan University of Science and Technology in Irbid, Jordan, the JRTR received its operation license on November 2017. The JRTR has also received its license from the Jordan Food and Drug Administration to distribute its iodine-131 product line, which consists of various dosages of the isotope in both liquid and capsule form. Iodine-131 is a radioactive isotope of iodine that is often used in radiopharmaceuticals for diagnosing and treating diseases, such as thyroid cancer. The JRTR supplies radiopharmaceuticals to 13 medical centres in Jordan and is continuing to expand its clientele. Plans are under way to expand the JRTR’s radiopharmaceutical products and to provide other irradiation services, such as the production of silicon, with specifications suitable to the electronics industry.